Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.

This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...

DraftKings (NASDAQ: DKNG) is forecasting robust growth in revenue and profitability in 2025. Read More: Earn up to $845 cash ...

The overall value in Carnival stock is compelling here, making it more a buy than a sell or even a hold. This was an industry ...

Stodgy tobacco stock Altria Group ( MO 0.18%), most known for selling Marlboro cigarettes in the U.S. and paying hefty ...

The FFHH crew previews Week 10, highlighting three exciting matchups, including a Monday Night Football battle between Tyreek ...

Entergy has strong growth potential but appears overvalued. See why ETR stock’s favorable regulatory environment and dividend ...

Moreover, the proliferation of exotic exchange-traded funds (ETFs) is fueling this trend. Today, investors seeking to ...

Here's the complete list of investment and trading ideas for the day. Buy Sansera Engineering shares in the cash segment for ...

Chandan Taparia has recommended three stocks to buy today – Infosys, Bank of Baroda, and Power Finance Corporation ...

AstraZeneca's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, and diabetes medicine Farxiga are expected ...

The brokerage reiterated its 'Buy' rating on the stock with a revised target price of Rs 2,235. When comparing Hyundai Motor ...